Status:
COMPLETED
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
Lead Sponsor:
Monteris Medical
Conditions:
Brain Tumor
Brain Tumor, Recurrent
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
Eligibility Criteria
Inclusion
- Previous diagnosis of GBM treated with radiotherapy with or without surgical resection and/or chemotherapy
- Clinical/radiographic suspicion of tumor recurrence/progression
Exclusion
- Previous treatment of target GBM with stereotactic radiosurgery, brachytherapy, or carmustine impregnated wafers (Gliadel).
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00747253
Start Date
August 1 2008
End Date
April 1 2010
Last Update
August 24 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
2
Cleveland Clinic Foundation, 9500 Euclid Ave
Cleveland, Ohio, United States, 44195